Wells Fargo & Company Oyster Point Pharma, Inc. Transaction History

Wells Fargo & Company

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$7.95 - $11.68 $23 - $35	3 Added 2.68%	115 $1,000
Q3 2022 Nov 14, 2022	BUY	$4.41 - $8.38 $114 - $217	26 Added 30.23%	112 $1,000
Q2 2022 Aug 12, 2022	BUY	$3.6 - $11.2 $309 - $963	86 New	86 $0
Q1 2022 May 16, 2022	SELL	$8.58 - $17.65 $33,041 - $67,970	-3,851 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$10.17 - $18.96 $39,164 - $73,014	3,851 New	3,851 $70,000
Q3 2021 Nov 15, 2021	SELL	$11.67 - $18.07 $1,482 - $2,294	-127 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$16.25 - $21.51 $28,551 - $37,793	-1,757 Reduced 93.26%	127 $2,000
Q1 2021 May 13, 2021	SELL	$17.92 - $25.86 $198,481 - $286,425	-11,076 Reduced 85.46%	1,884 $34,000
Q4 2020 Feb 09, 2021	BUY	$18.13 - $25.18 $136,065 - $188,975	7,505 Added 137.58%	12,960 $244,000
Q3 2020 Nov 05, 2020	SELL	$17.83 - $29.12 $23,981 - $39,166	-1,345 Reduced 19.78%	5,455 $115,000
Q2 2020 Aug 13, 2020	BUY	$27.86 - $35.93 $80,654 - $104,017	2,895 Added 74.14%	6,800 $196,000
Q1 2020 May 14, 2020	BUY	$23.65 - $40.96 $92,353 - $159,948	3,905 New	3,905 $137,000

19K

Ticker OYST
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,831,500
Description
Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry ...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.